Scarica l'app Stockscreener
42.91
1.42%
0.545
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
State of New Jersey Common Pension Fund D Reduces Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Australia's Orica gains after positive H2 performance update - XM
ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Buy Rating from HC Wainwright - Defense World
Orica Updates Segments and Reports Solid Performance - TipRanks
Otis Worldwide Co. (NYSE:OTIS) Shares Sold by Wealthspire Advisors LLC - Defense World
Introducing Our Rant Against Ionis Pharmaceuticals Inc - US Post News
Nothing is Better Than Ionis Pharmaceuticals Inc (IONS) stock at the moment - SETE News
Examining OTIS’s book value per share for the latest quarter - US Post News
Investors in cash trouble should check out IO Biotech Inc (IOBT) - SETE News
IO Biotech (NASDAQ:IOBT) Rating Reiterated by HC Wainwright - Defense World
IO Biotech (NASDAQ:IOBT) PT Raised to $6.00 - Defense World
BMO Capital Markets analysts downgrades a Market perform rating for Ionis Pharmaceuticals Inc (IONS) - Knox Daily
IO Biotech Inc [IOBT] moved up 3.22: Why It’s Important - The DBT News
OSI Systems (NASDAQ:OSIS) Sees Unusually-High Trading Volume - MarketBeat
ORIX (NYSE:IX) Shares Gap Down to $122.44 - MarketBeat
Oric Pharmaceuticals, OpenBench launch discovery collaboration - TipRanks
OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration - PR Newswire
The ORIC Pharmaceuticals Inc (ORIC) had a good session last reading, didn’t it? - US Post News
In the Green: Ionis Pharmaceuticals Inc (IONS) Closes at 40.70, Up/Down -3.53 from Previous Day - The Dwinnex
Otis Worldwide Corp [OTIS] Investment Guide: What You Need to Know - Knox Daily
Ionos drops after Warburg Pincus places shares - XM
(OMI) Long Term Investment Analysis - Stock Traders Daily
Recent Insider Activity Suggests Potential Gains for Owens & Minor, Inc. (OMI) - Knox Daily
Otis Worldwide Corp. stock rises Monday, outperforms market - MarketWatch
Multiple System Atrophy Market on Track for Major Expansion - openPR
Analyzing IO Biotech Inc (IOBT) After Recent Trading Activity - Knox Daily
IOBT (IO Biotech Inc) has impressive results - US Post News
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study - Zacks Investment Research
Negative FDA AdCom vote on Ocaliva - The Pharma Letter
Analytical Overview: ORIC Pharmaceuticals Inc (ORIC)’s Ratios Tell a Financial Story - The Dwinnex
Market Momentum: IO Biotech Inc (IOBT) Registers a -2.20 Decrease, Closing at 0.75 - The Dwinnex
Principal Financial Group Inc. Sells 12,366 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of - EIN News
OSI Systems executive sells over $160k in company stock By Investing.com - Investing.com Australia
Otis Worldwide Corp. stock rises Friday, outperforms market - MarketWatch
Street cheering Immuneering’s phase IIa pancreatic data - BioWorld Online
January 2026 Options Now Available For Ionis Pharmaceuticals - Nasdaq
PFG Investments LLC Sells 127 Shares of Otis Worldwide Co. (NYSE:OTIS) - Defense World
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to Post Q3 2024 Earnings of ($0.92) Per Share, Leerink Partnrs Forecasts - MarketBeat
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering - MSN
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering - Zacks Investment Research
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering - Yahoo Finance
Ionis Pharmaceuticals announces $500 million public offering | Biotechnology | The Pharmaletter - The Pharma Letter
FY2028 EPS Estimates for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Increased by Analyst - MarketBeat
Ionis announces pricing of $500.3 million public offering - MSN
SEC Form 424B5 filed by Ionis Pharmaceuticals Inc. - Quantisnow
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Down to $48.33 - MarketBeat
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - MSN
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Ionis Pharmaceuticals plans $500 million stock offering - Investing.com
Ionis Pharmaceuticals announces public stock offering - Investing.com
Ionis announces proposed public offering of common stock - The Malaysian Reserve
Ionis announces pricing of $500.3 million public offering - Financial Times
Ionis announces pricing of $500.3 million public offering - Nasdaq
Ionis Pharmaceuticals plans $500 million stock offering - Investing.com India
Ionis Pharmaceuticals plans $500 million stock offering By Investing.com - Investing.com Canada
Ionis Pharmaceuticals plans $500 million stock offering By Investing.com - Investing.com UK
Ionis announces proposed public offering of common stock - Financial Times
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Purchased by TD Asset Management Inc - MarketBeat
AstraZeneca Believes Size Matters In Amyloidosis - Scrip
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives $60.68 Average PT from Brokerages - MarketBeat
EVP Research Swayze Eric acquired $425 worth of shares (11 units at $38.64), increasing direct ownership by 0.03% to 34,907 units (SEC Form 4) - Quantisnow
EVP CLO & General Counsel O'Neil Patrick R. acquired $9,506 worth of shares (246 units at $38.64), increasing direct ownership by 0.51% to 48,873 units (SEC Form 4) - Quantisnow
IgA Nephropathy Market to Show Remarkable Growth Trends from - openPR
The Globe and Mail - The Globe and Mail
Amyotrophic Lateral Sclerosis Market to Show Remarkable Growth - openPR
Amyotrophic Lateral Sclerosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Amylyx Pharma, Ionis Pharma, Annexon, Inc., UniQure Biopharma, Sangamo Therapeutics - Barchart
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA - Quantisnow
Amendment: EVP, Finance & CFO Hougen Elizabeth L sold $107,105 worth of shares (2,162 units at $49.54), decreasing direct ownership by 2% to 92,868 units (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $15,731.20 in Stock - MarketBeat
Ionis Pharmaceuticals executive sells over $32k in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals executive sells over $32k in stock - Investing.com
Ionis Pharmaceuticals executive sells over $32k in stock By Investing.com - Investing.com UK
EVP, Chief Development Officer Geary Richard S sold $32,159 worth of shares (651 units at $49.40), decreasing direct ownership by 0.76% to 84,823 units (SEC Form 4) - Quantisnow
Arrowhead chases Ionis in rare, genetic disease race - BioWorld Online
1.13%
2.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):